Timing disparity of hepatocellular carcinoma (HCC) recurrence in a patient receiving interferon and subsequent direct antiviral agent (DAA) therapy for chronic hepatitis C | Zendy

AI Assistant Blog Pricing

Timing disparity of hepatocellular carcinoma (HCC) recurrence in a patient receiving interferon and subsequent direct antiviral agent (DAA) therapy for chronic hepatitis C

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.